{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "retrospective cohort study"
      },
      "Participants": {
        "score": 2,
        "evidence": "487,676 patients with aECAD"
      },
      "Intervention": {
        "score": 2,
        "evidence": "CEA and CAS on AD and non\u2010AD dementia incidence"
      },
      "Objective": {
        "score": 1,
        "evidence": "evaluate the effect of CEA and CAS on AD and non\u2010AD dementia incidence"
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "37,317 patients underwent CEA or CAS"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "CEA was associated with a significantly lower AD risk (relative risk = 0.93; 95% confidence interval, 0.86\u20130.99; P < 0.05)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  },
  "model": "gpt-4o"
}